CEL-SCI (NYSE:CVM) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of CEL-SCI (NYSE:CVM) in a report published on Friday. The brokerage issued a sell rating on the stock.

CEL-SCI Trading Up 6.1 %

NYSE:CVM opened at $0.42 on Friday. The company has a current ratio of 1.31, a quick ratio of 1.09 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $30.76 million, a price-to-earnings ratio of -0.81 and a beta of 0.65. The business’s 50-day moving average price is $0.55 and its two-hundred day moving average price is $0.89. CEL-SCI has a 1-year low of $0.36 and a 1-year high of $3.08.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Calton & Associates Inc. bought a new position in CEL-SCI during the third quarter worth about $50,000. Plotkin Financial Advisors LLC acquired a new stake in CEL-SCI during the 3rd quarter valued at $98,000. Renaissance Technologies LLC raised its position in shares of CEL-SCI by 29.9% in the second quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock valued at $202,000 after purchasing an additional 40,000 shares during the period. Finally, Geode Capital Management LLC grew its stake in CEL-SCI by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after buying an additional 53,879 shares during the last quarter. 12.08% of the stock is owned by institutional investors and hedge funds.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.